Business
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS) LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected ...
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase","length":156,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":304,"olType":false},{"type":"text","content":"ESTERO, FL / ACCESS Newswire / April 20, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company") today announced that it has closed the second and final tranche of the private placement announced on February 11, 2026 (the "Offering") for the purchase and sale of 26,250 shares of Series A Convertible Preferred Stock.","length":372,"tagName":"p"},{"type":"text","content":"Pursuant to the closing of the second and final tranche of the Offering, the Company issued an aggregate of 12,500 Preferred Shares for gross proceeds of $10.0 million. With the completion of this tranche of the Offering, total aggregate gross proceeds to the Company were $21.0 million, before deducting placement agent fees and other offering expenses. Based on the total proceeds, the Company's stockholders' equity now exceeds the $2.5 million minimum required to maintain its listing on the Nasdaq Capital Market.","length":526,"tagName":"p"},{"type":"text","content":"The Company intends to use the net proceeds from the transaction to support working capital, to fund a portion of the cash component of the proposed DCS acquisition, and other general corporate purposes.","length":203,"tagName":"p"},{"type":"text","content":"Additional information regarding the Offering is available in the Company's Current Report on Form 8-K/A filed on April 17, 2026 with the SEC.","length":146,"tagName":"p"},{"type":"text","content":""Finalizing this $21 million raise is a transformative step for Aspire," said Kraig Higginson, Interim CEO. "These funds solidify our capital position as we advance our sublingual delivery platform and accelerate consumer awareness and retail expansion of BUZZ BOMB™, our innovative caffeine product. Simultaneously, we are executing a dual-track growth strat...